Changes in L-phenylalanine concentration reflect and predict response to anti-PD-1 treatment combined with chemotherapy in patients with non-small cell lung cancer

Abstract

Chemotherapy combined with checkpoint blockade antibodies targeting programmed cell death protein (PD-1) has achieved remarkable success in non-small cell lung cancer. However, few patients benefit from long-term treatment. Therefore, biomarkers capable of guiding the optimal therapeutic selection and reducing unnecessary toxicity are of pressing importance. In our research, we gathered serial blood samples from two groups of non-small cell lung cancer patients: 49 patients received a combination of therapies, and 34 patients went under chemotherapy alone. Utilizing non-targeted metabolomic analysis, we examined different metabolites’ disparity. Among the lot, L-phenylalanine emerged as a significant prognostic marker in the combination treatment of non-small cell lung cancer patients, interestingly absent in patients under sole chemotherapy. The reduced ratio of L-phenylalanine concentration (two-cycle treatment vs. pre-treatment) was associated with improved progression-free survival (hazard ratio = 1.8000, 95% confidence interval: 0.8566–3.7820, p < 0.0001) and overall survival (hazard ratio = 1.583, 95% confidence interval: 0.7416–3.3800, p < 0.005). We further recruited two validation cohorts (cohort 1: 40 patients and cohort 2: 30 patients) to validate the sensitivity and specificity of L-phenylalanine prediction. Our results demonstrate that a model based on L-phenylalanine variations could serve as an early risk-assessment tool for non-small cell lung cancer patients undergoing treatment, potentially facilitating strategic clinical decision-making.

Keywords

immunotherapy / non-targeted metabolomics / NSCLC / serum metabolomics

References

[1] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1): 17-48.

[2] Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021; 398(10299): 535-554.

[3] Buriolla S, Pelizzari G, Corvaja C, et al. Immunotherapy in NSCLC patients with brain metastases. Int J Mol Sci. 2022; 23(13): 7068.

[4] Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018; 36(17): 1675-1684.

[5] Liao CX, Deng CS, Liang X, et al. PD-1 blockade and radiotherapy combination for advanced Epstein–Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review. Front Immunol. 2023; 14: 1239168.

[6] Yang F, Wang JF, Wang Y, Liu B, Molina JR. Comparative analysis of predictive biomarkers for PD-1/PD-L1 inhibitors in cancers: developments and challenges. Cancers (Basel). 2021; 14(1): 109.

[7] Frega G, Cossio FP, Banales JM, et al. Lacking immunotherapy biomarkers for biliary tract cancer: a comprehensive systematic literature review and meta-analysis. Cells. 2023; 12(16): 2098.

[8] Palmeri M, Mehnert J, Silk AW, et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 2022; 7(1): 100336.

[9] Mithoowani H, Febbraro M. Non-small-cell lung cancer in 2022: a review for general practitioners in oncology. Curr Oncol. 2022; 29(3): 1828-1839.

[10] Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022; 15(1): 131.

[11] Liu J, Zhang Y. Intratumor microbiome in cancer progression: current developments, challenges and future trends. Biomark Res. 2022; 10(1): 37.

[12] Song R, Liu F, Ping Y, Zhang Y, Wang L. Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction. Biomark Res. 2023; 11(1): 57.

[13] Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005; 122(1): 107-118.

[14] Li C, You X, Xu X, et al. A metabolic reprogramming amino acid polymer as an immunosurveillance activator and leukemia targeting drug carrier for T-cell acute lymphoblastic leukemia. Adv Sci (Weinh). 2022; 9(9): e2104134.

[15] Gong J, Chehrazi-Raffle A, Placencio-Hickok V, Guan M, Hendifar A, Salgia R. The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. Clin Transl Med. 2019; 8(1): 9.

[16] Yang L, Li A, Wang Y, Zhang Y. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduct Target Ther. 2023; 8(1): 35.

[17] Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015; 43(3): 435-449.

[18] Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD, McLean JA. Untargeted metabolomics strategies—challenges and emerging directions. J Am Soc Mass Spectrom. 2016; 27(12): 1897-1905.

[19] van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM. Phenylketonuria. Nat Rev Dis Primers. 2021; 7(1): 36.

[20] Rovelli V, Longo N. Phenylketonuria and the brain. Mol Genet Metab. 2023; 139(1): 107583.

[21] Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010; 376(9750): 1417-1427.

[22] Gostner JM, Becker K, Kurz K, Fuchs D. Disturbed amino acid metabolism in HIV: association with neuropsychiatric symptoms. Front Psychiatry. 2015; 6: 97.

[23] Demirdas S, Coakley KE, Bisschop PH, Hollak CE, Bosch AM, Singh RH. Bone health in phenylketonuria: a systematic review and meta-analysis. Orphanet J Rare Dis. 2015; 10: 17.

[24] Roth E, Zoch G, Schulz F, et al. Amino acid concentrations in plasma and skeletal muscle of patients with acute hemorrhagic necrotizing pancreatitis. Clin Chem. 1985; 31(8): 1305-1309.

[25] Rath T, Roth E, Keidl R, Meissl G. Phenylalanine: total amino acid ratio in 45 burn patients. Scand J Plast Reconstr Surg Hand Surg. 1987; 21(3): 297-300.

[26] Ollenschlager G, Jansen S, Schindler J, Rasokat H, Schrappe-Bacher M, Roth E. Plasma amino acid pattern of patients with HIV infection. Clin Chem. 1988; 34(9): 1787-1789.

[27] Mizushima T, Ochi K, Koide N. [Metabolic disorders of patients with acute pancreatitis: carbohydrate, lipid and protein metabolic disorders]. Nihon Rinsho. 2004; 62(11): 1989-1992.

[28] Geiger R, Rieckmann JC, Wolf T, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016; 167(3): 829-842.e13.

[29] Ping Y, Shan J, Liu Y, et al. Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8(+) T cell function. Cancer Immunol Immunother. 2023; 72(4): 1015-1027.

[30] Guo C, You Z, Shi H, et al. SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. Nature. 2023; 620(7972): 200-208.

[31] Yang B, Wang X, Ren X. Amino acid metabolism related to immune tolerance by MDSCs. Int Rev Immunol. 2012; 31(3): 177-183.

[32] Sikalidis AK. Amino acids and immune response: a role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer? Pathol Oncol Res. 2015; 21(1): 9-17.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.